Anti-hepatocellular carcinoma activity of the cyclin-dependent kinase inhibitor AT7519.

[1]  N. Homer,et al.  Analysis of AT7519 as a pro-resolution compound in an acetaminophen-induced mouse model of acute inflammation by UPLC-MS/MS , 2023, Journal of Inflammation.

[2]  Yanxiang Zhao,et al.  An autophagy-inducing stapled peptide promotes c-MET degradation and overrides adaptive resistance to sorafenib in c-MET+ hepatocellular carcinoma , 2022, Biochemistry and biophysics reports.

[3]  R. Bernards,et al.  Evolving therapeutic landscape of advanced hepatocellular carcinoma , 2022, Nature Reviews Gastroenterology & Hepatology.

[4]  T. Lee,et al.  Wnt/β-Catenin Signaling as a Driver of Stemness and Metabolic Reprogramming in Hepatocellular Carcinoma , 2022, Cancers.

[5]  P. Dong,et al.  A review on the role of cyclin dependent kinases in cancers , 2022, Cancer Cell International.

[6]  Chih-Hung Hsu,et al.  Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma , 2022, Oncology.

[7]  Jhin Jieh Lim,et al.  Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors , 2022, Journal of experimental & clinical cancer research : CR.

[8]  Yunhui Li,et al.  DUB3/KLF4 combats tumor growth and chemoresistance in hepatocellular carcinoma , 2022, Cell death discovery.

[9]  Jianfeng Ren,et al.  Comparative transcriptome analyses unravel the response to acute thermal stress in the razor clam, Sinonovacula constricta , 2022, Aquaculture Reports.

[10]  Y. Pu,et al.  CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells , 2022, Disease markers.

[11]  P. Chow,et al.  The altered lipidome of hepatocellular carcinoma. , 2022, Seminars in cancer biology.

[12]  Rizwan Ahamed,et al.  Hepatocellular Carcinoma in 2021: An Exhaustive Update , 2021, Cureus.

[13]  H. Woo,et al.  Tumor suppressor RBM24 inhibits nuclear translocation of CTNNB1 and TP63 expression in liver cancer cells , 2021, Oncology letters.

[14]  Xing-Xing He,et al.  Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets , 2021, Journal of Experimental & Clinical Cancer Research.

[15]  H. Shimizu,et al.  Treatment of Retinoblastoma 1–Intact Hepatocellular Carcinoma With Cyclin‐Dependent Kinase 4/6 Inhibitor Combination Therapy , 2021, Hepatology.

[16]  Wenjun Chang,et al.  Interaction of Hepatitis B Virus X Protein with the Pregnane X Receptor Enhances the Synergistic Effects of Aflatoxin B1 and Hepatitis B Virus on Promoting Hepatocarcinogenesis , 2021, Journal of clinical and translational hepatology.

[17]  G. Ahlenstiel,et al.  Immune-checkpoint inhibitors for advanced hepatocellular carcinoma: a synopsis of response rates. , 2021, The oncologist.

[18]  Qiong Wu,et al.  The regulatory roles and mechanisms of the transcription factor FOXF2 in human diseases , 2021, PeerJ.

[19]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[20]  X. Fang,et al.  GATA3 is downregulated in HCC and accelerates HCC aggressiveness by transcriptionally inhibiting slug expression , 2021, Oncology letters.

[21]  Wenjiao Zeng,et al.  Wnt8B, transcriptionally regulated by ZNF191, promotes cell proliferation of hepatocellular carcinoma via Wnt signaling , 2020, Cancer science.

[22]  Minoru Kanehisa,et al.  KEGG: integrating viruses and cellular organisms , 2020, Nucleic Acids Res..

[23]  Wei Wang,et al.  PARP6 suppresses the proliferation and metastasis of hepatocellular carcinoma by degrading XRCC6 to regulate the Wnt/β-catenin pathway. , 2020 .

[24]  E. D. De Toni,et al.  The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects , 2020, Signal Transduction and Targeted Therapy.

[25]  J. Marin,et al.  Molecular Bases of Drug Resistance in Hepatocellular Carcinoma , 2020, Cancers.

[26]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[27]  Junfei Jin,et al.  Human alkaline ceramidase 2 promotes the growth, invasion, and migration of hepatocellular carcinoma cells via sphingomyelin phosphodiesterase acid‐like 3B , 2020, Cancer science.

[28]  Joachim Goedhart,et al.  VolcaNoseR is a web app for creating, exploring, labeling and sharing volcano plots , 2020, Scientific Reports.

[29]  N. Agarwal,et al.  Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma , 2020, Cancer management and research.

[30]  Pablo Arbeláez,et al.  An image J plugin for the high throughput image analysis of in vitro scratch wound healing assays , 2020, bioRxiv.

[31]  S. Chen‐Kiang,et al.  Targeting CDK4/6 in mantle cell lymphoma. , 2020, Annals of lymphoma.

[32]  A. Satyanarayana,et al.  Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma , 2020, Cancers.

[33]  Runan Yao,et al.  ShinyGO: a graphical gene-set enrichment tool for animals and plants , 2019, Bioinform..

[34]  Xiaofan Ding,et al.  Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas. , 2019, Gastroenterology.

[35]  Haixia Chen,et al.  Altered short chain fatty acid profiles induced by dietary fiber intervention regulate AMPK levels and intestinal homeostasis. , 2019, Food & function.

[36]  Fangxing Peng,et al.  Hepatitis B Virus X Protein-Induced RORγ Expression to Promote the Migration and Proliferation of Hepatocellular Carcinoma , 2019, BioMed research international.

[37]  J. Dastych,et al.  The Dichotomous Nature of AZ5104 (an EGFR Inhibitor) Towards RORγ and RORγT , 2019, International journal of molecular sciences.

[38]  Zujiang Yu,et al.  Role of cyclin‐dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

[39]  R. Bernards,et al.  CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma , 2019, Gut.

[40]  Steven L Salzberg,et al.  Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype , 2019, Nature Biotechnology.

[41]  M. Deng,et al.  Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression , 2019, Cell Communication and Signaling.

[42]  M. Heikenwalder,et al.  From NASH to HCC: current concepts and future challenges , 2019, Nature Reviews Gastroenterology & Hepatology.

[43]  D. Zheng,et al.  Cyclin-dependent kinase inhibitor 2B gene is associated with the sensitivity of hepatoma cells to Sorafenib , 2019, OncoTargets and therapy.

[44]  Ling Wang,et al.  Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer. , 2019, Biochemical and biophysical research communications.

[45]  I. Mills,et al.  CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation , 2019, Neoplasia.

[46]  J. Dastych,et al.  SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib , 2019, Cancers.

[47]  H. Baba,et al.  Lysyl oxidase induces epithelial‐mesenchymal transition and predicts intrahepatic metastasis of hepatocellular carcinoma , 2019, Cancer science.

[48]  Xiaoliang Chen,et al.  Krüppel‐like factor 2 inhibits hepatocarcinogenesis through negative regulation of the Hedgehog pathway , 2019, Cancer science.

[49]  M. Ávila,et al.  Epigenetic events involved in organic cation transporter 1‐dependent impaired response of hepatocellular carcinoma to sorafenib , 2019, British journal of pharmacology.

[50]  Dominik Strapagiel,et al.  Digoxin, an Overlooked Agonist of RORγ/RORγT , 2019, Front. Pharmacol..

[51]  J. Dastych,et al.  The cardenolides strophanthidin, digoxigenin and dihydroouabain act as activators of the human RORγ/RORγT receptors. , 2018, Toxicology letters.

[52]  U. Knippschild,et al.  The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma , 2018, International journal of molecular sciences.

[53]  Wei Chen,et al.  The Oncogenic Role of ARG1 in Progression and Metastasis of Hepatocellular Carcinoma , 2018, BioMed research international.

[54]  Guangyi Jiang,et al.  High expression of ERCC5 predicts a poor prognosis in hepatocellular carcinoma. , 2018, International journal of clinical and experimental pathology.

[55]  T. Greten,et al.  Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research , 2018, Nature Reviews Gastroenterology & Hepatology.

[56]  T. Efferth,et al.  Molecular bases of the poor response of liver cancer to chemotherapy. , 2018, Clinics and research in hepatology and gastroenterology.

[57]  Jae-Hoon Jeong,et al.  Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS‑032, on cervical cancer. , 2018, International journal of oncology.

[58]  Yiming Zhao,et al.  Dihydropyrimidine dehydrogenase predicts survival and response to interferon-α in hepatocellular carcinoma , 2018, Cell Death & Disease.

[59]  Esther S. Kim,et al.  Abemaciclib: First Global Approval , 2017, Drugs.

[60]  X. Liang,et al.  Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma , 2017, Cancer medicine.

[61]  P. Cramer,et al.  CDK9-dependent RNA polymerase II pausing controls transcription initiation , 2017, eLife.

[62]  Guang-shun Yang,et al.  Overexpression of RAS-Association Domain Family 6 (RASSF6) Inhibits Proliferation and Tumorigenesis in Hepatocellular Carcinoma Cells , 2017, Oncology research.

[63]  Liyuan Sun,et al.  FOXF2 deficiency promotes hepatocellular carcinoma metastasis by inducing mesenchymal-epithelial transition. , 2017, Cancer biomarkers : section A of Disease markers.

[64]  L. Seymour,et al.  The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group , 2017, Leukemia & lymphoma.

[65]  Yahiya Y. Syed.  Ribociclib: First Global Approval , 2017, Drugs.

[66]  J. Meng.  Distinct functions of dynamin isoforms in tumorigenesis and their potential as therapeutic targets in cancer , 2017, Oncotarget.

[67]  B. Slagle,et al.  Farnesoid X receptor ablation sensitizes mice to hepatitis b virus X protein–induced hepatocarcinogenesis , 2017, Hepatology.

[68]  J. Llovet,et al.  Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma , 2016, Gut.

[69]  N. Waterhouse,et al.  Measuring Survival of Adherent Cells with the Colony-Forming Assay. , 2016, Cold Spring Harbor protocols.

[70]  F. Liu,et al.  EVI1 promotes cell proliferation in HBx-induced hepatocarcinogenesis as a critical transcription factor regulating lncRNAs , 2016, Oncotarget.

[71]  W-S Guo,et al.  DNM3 Attenuates Hepatocellular Carcinoma Growth by Activating P53 , 2016, Medical science monitor : international medical journal of experimental and clinical research.

[72]  Chiun Hsu,et al.  Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression , 2015, Clinical Cancer Research.

[73]  D. Yoon,et al.  Hepatitis B virus X promotes hepatocellular carcinoma development via nuclear protein 1 pathway. , 2015, Biochemical and biophysical research communications.

[74]  F. He,et al.  FXR induces SOCS3 and suppresses hepatocellular carcinoma , 2015, Oncotarget.

[75]  R. Versteeg,et al.  Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma , 2015, Clinical Cancer Research.

[76]  Shan Huang,et al.  Lysyl Oxidase Is Predictive of Unfavorable Outcomes and Essential for Regulation of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma , 2015, Digestive Diseases and Sciences.

[77]  Sohita Dhillon.  Palbociclib: First Global Approval , 2015, Drugs.

[78]  S. Salzberg,et al.  StringTie enables improved reconstruction of a transcriptome from RNA-seq reads , 2015, Nature Biotechnology.

[79]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[80]  L. Seymour,et al.  A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177 , 2014, British Journal of Cancer.

[81]  S. Zahler,et al.  Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach. , 2014, Journal of hepatology.

[82]  A. Raza,et al.  Hepatocellular carcinoma review: current treatment, and evidence-based medicine. , 2014, World journal of gastroenterology.

[83]  Jukka Westermarck,et al.  ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays , 2014, PloS one.

[84]  M. Yano,et al.  Hepatitis B virus X induces cell proliferation in the hepatocarcinogenesis via up‐regulation of cytoplasmic p21 expression , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[85]  O. Briz,et al.  Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib , 2013, Hepatology.

[86]  P. Kaldis,et al.  Cdks, cyclins and CKIs: roles beyond cell cycle regulation , 2013, Development.

[87]  A. Yoshimura,et al.  CDK inhibitors suppress Th17 and promote iTreg differentiation, and ameliorate experimental autoimmune encephalomyelitis in mice. , 2013, Biochemical and biophysical research communications.

[88]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[89]  B. Lewis,et al.  Krüppel-Like Factor 4, a Tumor Suppressor in Hepatocellular Carcinoma Cells Reverts Epithelial Mesenchymal Transition by Suppressing Slug Expression , 2012, PloS one.

[90]  Jan-Gowth Chang,et al.  Decreased expression of p39 is associated with a poor prognosis in human hepatocellular carcinoma , 2011, Medical oncology.

[91]  R. Plummer,et al.  A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[92]  J. Dastych,et al.  Aflatoxins upregulate CYP3A4 mRNA expression in a process that involves the PXR transcription factor. , 2011, Toxicology letters.

[93]  Y. Maehara,et al.  Evaluation of ERCC1 Expression for Cisplatin Sensitivity in Human Hepatocellular Carcinoma , 2011, Annals of Surgical Oncology.

[94]  S. Kwon,et al.  Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. , 2011, Gastroenterology.

[95]  Jung-Hwan Yoon,et al.  Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells. , 2010, Cancer letters.

[96]  Y. Jeng,et al.  Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC , 2010, BMC Cancer.

[97]  M Ladetto,et al.  AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition , 2010, Oncogene.

[98]  Yan Liu,et al.  Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment , 2010, Environmental health perspectives.

[99]  Scott A. Busby,et al.  The Benzenesulfoamide T0901317 [N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] Is a Novel Retinoic Acid Receptor-Related Orphan Receptor-α/γ Inverse Agonist , 2010, Molecular Pharmacology.

[100]  Laura A. Solt,et al.  Modulation of Retinoic Acid Receptor-related Orphan Receptor α and γ Activity by 7-Oxygenated Sterol Ligands* , 2009, The Journal of Biological Chemistry.

[101]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[102]  J. Lyons,et al.  Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines , 2009, Molecular Cancer Therapeutics.

[103]  Paul G Wyatt,et al.  Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.

[104]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[105]  M. Radtke,et al.  Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics , 2006, Cancer Chemotherapy and Pharmacology.

[106]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[107]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[108]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[109]  H. Adami,et al.  Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma , 2000, International journal of cancer.

[110]  G. Jay,et al.  HBx gene of hepatitis B virus induces liver cancer in transgenic mice , 1991, Nature.

[111]  Q. Zheng,et al.  CDK inhibitors in cancer therapy, an overview of recent development. , 2021, American journal of cancer research.

[112]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.